Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Myriad Genetics (MYGN) PT Lifted to $42 at Mizuho Securities Post Q1; Remains Sidelined
November 4, 2015 8:50 AM EST
Piper Jaffray analyst William Quirk reiterated an Overweight rating and boosted his price target on Myriad Genetics (NASDAQ: MYGN) to $47.00 (from $45.00) following Q1 beat.
Quirk commented, "Myriad's 1Q16 revenue increased 9% yoy to $183.5M, above consensus of $177.9M (PJC: $177.6M). Adjusted EPS of $0.41 was above consensus'... More
November 4, 2015 7:21 AM EST
Leerink Partners analyst Dan Leonard lifted his price target on Myriad Genetics (NASDAQ: MYGN) to $46.00 (from $37.00) following solid Q1 results but maintained a Market Perform rating.
Leonard commented, "We are nudging up our FY16 estimates following MYGN's solid September quarter (F1Q),... More
November 3, 2015 4:14 PM EST
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.41, $0.06 better than the analyst estimate of $0.35. Revenue for the quarter came in at $183.5 million versus the consensus estimate of $177.89 million.
Myriad Genetics sees FY2015 EPS of $1.60-$1.65, versus the consensus of $1.64. Myriad Genetics sees FY2015... More
